more modest variation in plasma concentrations for a much larger collection of clinical analytes-including not only cholesterol measures, but also C-reactive protein (CRP), 2 hemoglobin A1c, and creatinine-is also both substantially heritable and strongly correlated with the risk of future disease (4 -32 ) . This observation underlies the possibility of genetic association studies of variation within the reference interval for a more comprehensive identification of biological processes involved in disease than may be feasible by analysis of rare cases of extreme variation.
For the past 3 years or so, it has been technically possible to perform genetic association studies on a genomewide scale for complex human traits, exemplified in this review by plasma-based analytes. What has emerged from publication of initial genomewide association studies (GWASs) are not only new functional relationships between complex traits and genetic loci in genic and nongenic regions of the genome, but also a set of principles for conducting a successful GWAS. This review focuses on these principles with emphasis on the use of GWASs for plasma-based analytes to better understand human disease, with examples from cardiovascular biology. Excellent reviews of GWAS techniques focused on dichotomous outcomes such as disease status can be found elsewhere (33) (34) (35) (36) .
Genomewide Genetic Variation in Human Populations
Almost always biallelic, single nucleotide polymorphisms (SNPs) are the most common form of genetic variation in the human genome, and are now known to number in excess of 12.8 million (dbSNP, build 128) (37 ) . At the same time, it now appears that a much smaller number, perhaps approximately 2-3 million SNPs, are common, meaning they have a minor allele (i.e., less common allele) frequency of at least 5%. In populations with European or Asian ancestry, even fewer SNPs-perhaps 300 000 to 500 000 -are necessary to sample the unique common genetic variation as a result of the correlation between SNPs or linkage disequilibrium (LD) (38, 39 ) . SNPs chosen as surrogates for others on the basis of LD are termed tag SNPs. Recent estimates suggest that about 80% of common SNPs can be captured with 300 000 tag SNPs with a minimum correlation (r 2 ) of 0.8 (40, 41 ) . Consistent with the "out-of-Africa" hypothesis for migration of ancestral humans (42 ) , identifying tag SNPs for African populations is more complex. Not only do African populations have a greater number of common SNPs, but also the variation is older than in European or Asian populations and thus has been exposed to more recombination. As a consequence, SNPs in African populations are less correlated (i.e., lower LD), and tagging common African SNP variation requires perhaps 500 000 to 1 000 000 SNPs (43) (44) (45) . In addition, population diversity within Africa, both north and south of the Sahara as well as east to west and between isolated communities, makes the choice of an ideal set of tag SNPs quite challenging in African ancestral populations.
SNP choice aside, recent miniaturization technologies allow measurement of genotypes for as many as 1 000 000 or more tag SNPs across the whole genome for an individual in a single experiment without prohibitive cost. In general terms, these technologies are chip-based and use sequence-specific probes arrayed on the chip surface to interrogate prespecified SNPs through fluorescent readouts (46, 47 ) . Genotypes for each SNP are determined by the intensity of fluorescent signals. In one implementation, the signal for homozygous genotypes of the 2 possible alleles are fluorescent signals of 2 alternative colors, for example red and green. The signal for heterozygous genotypes has both colors, each with half the intensity of the signal of either color alone from the homozygous genotypes.
Study Samples
Although many study designs are possible, this review focuses on the population-based setting, for which success is critically dependent on application of sound epidemiological practices in assembling the study cohort (for examples of other designs, see (48 -50 ) ). As with conventional epidemiology, the essential principle is to minimize the risk of confounding due to factors that are simultaneously correlated with both the outcome of interest (e.g., a clinical analyte) and the exposure of interest, here the frequency of SNP alleles. Because of historical patterns of migration and isolation of human populations tens to hundreds of thousands of years ago, the frequency of SNP alleles will be closely related to population ancestry predating the relative mobility of recent centuries (42, 51 ) . These same ancestral patterns may be accompanied by cultural characteristics, representing correlated exposures and potential sources of confounding. Although allele frequency does not vary across populations for most SNPs, alleles of many SNPs will be more prevalent in some populations than others (38, 40, 41, (43) (44) (45) , and it is most reliable to strive toward ancestral homogeneity when ascertaining samples for population-based genetic association. At the very least, homogeneity should be ensured on the basis of self-report.
Eliminating all ancestral diversity is difficult (if not theoretically impossible) among humans, however, and analytic techniques may be used to address confounding due to the residual diversity (52) (53) (54) (55) (56) . The basic approach relies on identifying a subset of SNPs whose allele or genotype frequencies are most variable across populations to provide quantitative estimates of ancestry for each individual in a study. These estimates can be used to account for potential confounding from the residual ancestral heterogeneity in statistical tests of association between SNPs and the outcome of interest, which may be a continuous clinical measure, e.g., a plasma-based clinical analyte or height, as follows. In a classic example, the analysis of height by GWAS among European-Americans found candidate variation in a gene encoding lactase activity (LCT) 3 (57 ) . The allele frequencies of LCT variants also vary across Europe, however, and after accounting for sub-European ancestry, the association between lactase genetic variation and height could no longer be demonstrated.
Even when the population is homogeneous, genetic analysis of clinical analytes may be confounded more directly by properties of the clinical assay. Use of several assay methods, each with different characteristics, in different subsets of the population may provide sources of inadvertent bias and confounding. Although not always feasible, the best way to avoid these issues is to use 1 set of specimen collection and storage procedures as well as 1 core laboratory for all plasma assays to be evaluated in a given GWAS. For example, in the Women's Genome Health Study (58 ) , a single core laboratory standardized by the Centers for Disease Control and Prevention has been used to assay a wide range of lipid, inflammatory, and hemostatic biomarkers in a cohort of nearly 28 000 individuals. By doing so, intraand interassay CVs due to assay characteristics are greatly minimized, reducing noise and increasing the likelihood of being able to observe genetic effects. Similarly, as all participants in this cohort had plasma collected, processed, stored, thawed, and assayed in an identical manner, variation in analyte concentrations resulting from sample processing is minimized, as is a concomitant potential for confounding of genetic signals.
More pernicious still may be direct interaction between the assay and genetic variation. The latter situation arises when the assay reagents are sensitive to the form of the analyte, as may happen with nonsynonymous SNPs in genes encoding protein analytes or when unlinked variation alters posttranslational modification of a protein analyte. For example, a widely used commercial assay for circulating plasma soluble intercellular adhesion molecule 1 (sICAM-1) is known not to recognize the K56M (rs5491) variant of ICAM-1 (59 ) . Furthermore, this variant has a prevalence of about 35% in African ancestral populations but Ͻ1% European Ancestral populations. As a result, heterozygote carriers of this variant have, on average, half the mean sICAM-1 concentration of noncarriers when using this assay, whereas homozygous carriers have undetectable plasma sICAM-1. A genetic association study must account for this phenomenon (60 ) or risk falsely concluding that K56M is an extremely strong, population-dependent determinant of sICAM-1 levels.
Data Quality
Data quality with current platforms for whole genome genotyping is quite good and provides unambiguous genotype information for the vast majority of SNPs. Thus genotype assignment for these SNPs may be assured as long as the source DNA and assay procedures are adequate, as evidenced by successful genotypes for most (say, 90%) of the SNPs on the chip. Still, as with measurement of the clinical analytes, it is important to genotype all samples with the same procedures and in the same laboratory to diminish the risk of unnecessary genotyping biases (61, 62 ) . For a small number of SNPs, the raw data may still require more analysis or even visual inspection to discriminate between the 3 genotypes or to decide whether the genotyping assay is useful at all (63) (64) (65) . To some extent, the problem of faulty SNP data is being resolved experimentally, as the SNP assays in each new iteration of the genotyping platforms are increasingly robust (66, 67 ) . At the same time, recent improvements in algorithms for calling genotypes promise to improve treatment of problematic SNPs. Some recent data reduction strategies are conducted in a Bayesian framework and evaluate the probability of each of the 3 genotypes as a continuously valued rather than discrete quantity for use as prior information in hypothesis testing (68 ) . This approach may be helpful for the small minority of SNPs with marginal raw data, but significant associations involving SNPs with fundamentally ambiguous genotype calls ought still to be replicated using alternative genotyping assays that can discriminate the 3 genotypes cleanly.
SNPs passing quality control in the data reduction stage may also be flagged as suspicious if they have genotype frequencies grossly deviating from the proportions expected in a sample from a randomly mating population. These proportions, termed Hardy-Weinberg equilibrium, derive simply from the binomial distribution as f 1 2 for homozygotes of allele 1, 2 ϫ f 1 ϫ f 2 for the heterozygotes, and f 2 2 for homozygotes of allele 2 when f 1 and f 2 are the population frequencies of the 2 alleles of a biallelic SNP. With the current genotyping platforms, these deviations often arise from inability to distinguish heterozygous genotypes from homozygous genotypes in the raw data. Given the hundreds of thousands of genotyped SNPs for each sample, it is customary to exclude SNPs on the basis of deviation from expected Hardy-Weinberg equilibrium only when the evidence is overwhelming (e.g., P Ͻ 10 Ϫ6 ).
Hypothesis Testing
In the population-based design, the usual mode of hypothesis testing for association between genetic variation and a clinical analyte borrows from standard regression techniques. Often (but not always) there is a linear (also termed additive) relationship between the number of copies of the minor allele (0, 1, or 2) of an associated SNP and the plasma concentration of an analyte. Hypothesis testing is thus equivalent to regressing the (possibly normalized) analyte concentration against the minor allele count and rejecting the null hypothesis dependent on the significance of the regression coefficient. When effects are linear, the estimate of the coefficient provides a measure of the perallele genetic effect. Similarly, the estimate of the proportion of the variance explained by the genetic association in the linear model provides a measure of the total genetic effect, which will be closely related to statistical power (see below). At the same time, the regression formalism allows for many additional analyses, including adjustment for known influences of nongenetic covariates, adjustment for other genetic variants, model selection procedures, and interactions between SNPs and clinical covariates or other genetic variants. For example, to reduce the variance due to known, nongenetic factors and increase the relative effect of genetics, analyses of LDL cholesterol, CRP, or sICAM-1 may use residual values after adjustment for age, smoking status, blood pressure, obesity, and (among women) hormone replacement therapy use (60, 69, 70 ) . Highly efficient software for performing the regression analysis on a genomewide scale is freely available (53 ) . In theory, the relationship between allele count and analyte concentration need not be linear. Instead, the mean plasma concentrations for the 3 genotype groups could be independent, including cases in which the mean value for heterozygotes is not intermediate between the mean values for the 2 homozygous genotypes. More commonly, threshold effects dependent on 1 or 2 copies of an allele may occur. When either 1 or 2 copies of the minor allele have the same influence on the analyte concentration, the effect is termed dominant; when 2 copies of the minor allele are necessary for a differential concentration, the effect is termed recessive. Some analysis plans therefore perform regression by encoding the 3 genotype groups separately and allowing an additional degree of freedom in the hypothesis testing compared with the more constrained linear model. Setting 1 genotype, usually the most common genotype, as a reference, significance in this formalism can be determined for each of the nonreference genotypes, again by regression procedures. As under the linear assumption, the additional conveniences of the regression formalism can also be exploited in models based on genotype. In practice, though, only the most unusual modes of association will experience a loss of power when imposing the linear assumption in hypothesis testing. As long as the mean value for the heterozygous genotype is intermediate between the values for the homozygous genotypes and the minor allele frequency is not too low, the additive model will be adequate (71 ) .
The distribution of P values resulting from hypothesis testing of hundreds of thousands of SNPs in a GWAS can help evaluate study quality and also the likelihood of having discovered true associations. It is thus critically important to compare the distribution of P values from hypothesis testing to the uniform distribution expected under the null hypothesis, typically through the use of a quantile-quantile (QQ) plot. Deviations from the null throughout the distribution most often signify systematic inflation of the test statistic, usually due to heterogeneity in the sample related to ancestral admixture or, for clinical analytes, heterogeneity in the assay (Fig. 1A) . It can also result from systematic genotyping errors that eluded the initial quality controls. Deviation from the null among only the most significant SNPs (i.e., smallest P values), however, may be evidence for true associations. Because most GWAS test 300 000 to 1 000 000 SNPs per sample, perhaps tagging a total of 10 6 SNPs in non-Africans to 2 ϫ 10 6 SNPs in Africans, these deviations will only be evident for SNPs with P values smaller than 10 Ϫ5 to 10 Ϫ7 (Fig.  1B) (33, 35 ) . As a corollary, the genomewide level of statistical significance among non-African populations after correction for the multiple hypothesis testing by the Bonferroni procedure will require an uncorrected P value Ͻ0.05/10 6 ϭ 5 ϫ 10
Ϫ8
. Once candidate genomewide SNPs have been identified, repeating the analysis after adjusting analyte concentrations for these candidates usually results in P values that are largely restored to the expectation under the null, unless the adjustment reveals new conditional relationships with genomewide significance (Fig. 1C) . As a complement to the genomewide significance standard of P Ͻ 5 ϫ 10 Ϫ8 (33 ), procedures for estimating the fraction of false associations as a function of P value thresholds, also known as the false discovery rate, can be used to identify candidate SNPs for true association with analyte concentration on a genomewide basis (72 ) .
The preceding remarks are not meant to exclude other modes of analysis. To the contrary, genetic analysis of genomewide data in large populations continues to evolve as an area of intense research. It is certainly possible that some associations will be revealed only by haplotypes (combinations of neighboring SNPs considered simultaneously) instead of individual SNPs (73) (74) (75) (76) . Alternatively, some SNPs (or haplotypes) may act through effects on the variance of analyte concentration rather than on the mean. Further, some modes of association may be explained only by interaction with other clinical covariates, particularly when genotype-phenotype relationships are being sought to explain actual clinical events. As a classic example, the relationship between genetic variation in the alcohol dehydrogenase gene and incident myocardial infarction is, not surprisingly, mediated in part by the amount of alcohol consumption (77 ) . When the interaction variable is time or age, longitudinal analysis may be indicated (78 ) . The availability of plasma concentrations measured sequentially over a period of years in the same individual can aid greatly in this process. Finally, all of the analysis modes can be recast in terms of the Bayesian rather than the frequentist framework, especially as experience with GWAS continues to inform prior distributions for efficient effect estimates (79 -81 ) .
Neither the conventional analytic techniques nor the more intricate approaches in the preceding paragraph address the problem of assessing more modest yet true associations that may not meet genomewide significance. These relationships may not alter the bulk distribution of P values in a meaningful way (Fig. 1) and will be statistically indistinguishable from the vast majority of SNPs with P values less than nominal significance due to chance alone in a GWAS. The number of these modest associations will depend on the outcome of interest, but the ability to detect increasing numbers of true associations with increasing sample size for some clinical outcomes suggests that SNPs with modest effects can be expected (68 ) . To be sure, larger studies with tens or even hundreds of thousands of samples, either from single populations or accumulated through metaanalysis, will permit detection of modest associations (82, 83 ) . Alternatively, identifying these modestly associated SNPs may be possible with analytic methods that introduce prior biological knowledge to focus attention on SNPs most likely to influence an outcome of interest (84 -86 ) .
Power
Given the standard hypothesis testing formalism using linear regression and the additive assumption, it is instructive to explore the power for detecting genomewide associations with clinical analytes (or any other quantitative trait). The critical parameters in the power calculations are the sample size, which is often in the range of 1000 to 5000 individuals; the effect size, which can be summarized by the proportion of the variance explained by the 3 genotypes for a biallelic SNP; and finally the desired significance level, which is 5 ϫ 10
Ϫ8
for genomewide significance in non-African populations. Thus, at genomewide significance in a GWAS with 1000, 2000, or 5000 samples, the proportions of variance explained for 80% power are approximately 3.9%, 2.1%, or 0.8%, respectively ( Fig. 2A) . Under the additive assumption, the proportion of variance explained may be deconstructed into the combination of the per-allele shift in the (normalized) mean concentration of the clinical analyte and the minor allele frequency of the SNP. For example, in a study with 2000 samples, there would be 80% power for detecting shifts of about 0.25 SD or 9 mg/dL for the case of LDL cholesterol (SD is approximately 36 mg/dL in whites) for SNPs with minor allele frequency greater than about 0.2 ( Fig. 2A) . However, equivalent power for rarer minor alleles requires dramatically larger per-allele shifts in means. Below 5% minor allele frequency, the perallele shift required for genomewide significance becomes very large, and this trend underlies limiting population GWASs to associations with minor allele frequency in the range of 5%-50%. However, the threshold of 5% remains somewhat arbitrary, and some SNPs with minor allele in the range of 1%-5% may nonetheless have large enough effects on plasma analytes for adequate power with reasonable sample sizes. For example, a recently described SNP in PCSK9 (proprotein convertase subtilisin/kexin type 9) has minor allele frequency 1.6% and decreases LDL cholesterol by almost 0.5 SD while definitively decreasing cardiovascular risk (87, 88 ) .
Still, underpowered but true associations with lesser effects may be identified at genomewide significance in the discovery phase of a GWAS, and it is equally instructive to examine the distribution of P values arising from fluctuations due to sampling in a population-based study. The distributions can be quite broad, so that even genetic effects having considerably Ͻ80% power will still reach genomewide significance an appreciable part of the time. For example, with 2000 samples, effects explaining 1.5% of the variance will reach genomewide significance 52% of the time, although an effect explaining 2.1% of the variance is required for 80% power at genomewide significance. Effects explaining 1.0% of the variance will reach genomewide significance 16% of the time. These statistical fluctuations can also result in unwarranted pessimism or optimism about associations, since P values considerably larger than 10 Ϫ6 or smaller than 10
Ϫ14
will occur about 20% of the time, even when the genetic effects have nominal 80% power for genomewide significance (Fig. 2B) . For a clinical analyte, power to detect genetic effects on interindividual variation will also be influenced by intraindividual variation and variation in the assay determination. These last 2 quantities are related to measurement error, and as they increase, the proportion of the variance due to interindividual variation will decrease. Thus, power to detect genetic effects on interindividual variation will decrease as well. For a GWAS with 1000 -5000 samples, there is as much as a 15%-20% loss of power associated when up to 20% of the variance is attributable to the combination of intraindividual variation and measurement error (Fig. 2C) . For example, the CV for triglycerides can be as much as 30%, mostly due to intraindividual variability presumably related to fasting status (89 ) . With a population mean of about 140 mg/dL for triglycerides, this total measurement error will contribute as much as about 20% to the total variance and reduce power in a GWAS with 2000 samples as much as 20% for samples explaining 1.5%-2.0% of the interindividual variance (Fig.  2C) . For these reasons, GWASs targeting triglyceride concentrations may wish strict control on fasting status and other influences on intraindividual variation.
Confirmatory Studies: Replication and Validation
Whether adequately powered or not, SNP associations meeting genomewide significance should, in general, be confirmed by replication studies for 2 purposes (90 ). First, if performed with an alternative genotyping technology, replication reduces the possibility of apparent associations arising from systematic correlation between spurious genotypes and the clinical analyte. Second, when performed in a separately ascertained population, replication greatly reinforces the degree to which findings can be generalized. Following the discussion above, confirmation in a population with different clinical characteristics, environmental exposures, or, most dramatically, alternative ancestry may be particularly relevant for confirming the association. Recent examples of highly replicating associations for clinical analytes include data at the SORT1 (sortilin 1) locus for influences on LDL cholesterol and plasma apolipoprotein B (apoB), or the GCKR [glucokinase (hexokinase 4) regulator] locus for influences on triglycerides and the inflammatory marker CRP (32, 70, (91) (92) (93) (94) (95) . Highly confirmed loci for disease status have been identified for diabetes, aortic aneurysm, and cardiovascular events at 9p21. 3 (32, 68, 82, 96 -101 ) , for type 2 diabetes alone at several loci (32, 82, 102 ) , for type 1 diabetes (103 ), inflammatory bowel disease (104, 105 ) , macular degeneration at the CFH (complement factor H) and other loci (106 -108 ) , atrial fibrillation at 4q25 (109 ) , and both vascular events and statin response with KIF6 (kinesin family member 6) (110 -112 ) .
It is important to recognize that failure to replicate in an ancestrally different population need not invalidate a candidate association. It would not be surprising if differing LD relationships in ancestrally different populations would diminish the ability of a tag SNP chosen from one sample to adequately capture the causal SNP in a second sample. LD persistence in African ancestral populations, for example, averages half as many bases as in non-African populations (43, 45 ) . In comparing populations with divergent ancestry, it may be sensible to replicate by examining population-specific tag SNPs in a candidate region. As discussed above, ancestry may be related strongly enough to allele frequency to account for a failure to replicate. For example, factor V Leiden, one of the most important genetic determinants of venous thromboembolism, occurs in 5% to 8% of most European populations, where it is associated with a high attributable risk. However, replication of this effect would be difficult if not impossible in an Asian population, where factor V Leiden is rare (and likely as a consequence, the incidence of venous thrombosis is also far less frequent) (113 ) . Finally, the underlying epidemiology of the disease of interest may be as important as ancestral impact on allele frequency, and it is also not unreasonable to anticipate that different SNPs might have different associations by sex or according to different environmental exposures that may be ubiquitous in one geographic region but almost absent in another. It may not be possible to validate genetic variation that impacts the renin-angiotensin system in geographic zones, for example, with high salt intake in regions with low salt consumption or in populations with a low frequency of salt-sensitive hypertension (114 ) .
Recent results have addressed the value of internal replication, in which the main study population is divided into separate discovery and validation samples with essentially the same ascertainment (115 ) . In the discovery sample, SNPs are identified at one significance standard in the discovery sample, say genomewide significance. Then, these SNPs are validated in the second sample at a significance standard that is typically lower but adequate for nominal significance (P Ͻ 0.05) after Bonferroni correction for the small number of SNPs carried forward from discovery. However, it can be demonstrated, perhaps counterintuitively, that the 2-stage procedure has less statistical power than analysis in the whole sample at once, leaving validation best performed in separately ascertained, external samples. These same analytic findings suggest increasing use of metaanalysis in evaluating associations in several populations, rather than assigning somewhat arbitrary precedence to each population in a staged analysis plan (e.g., (82 ) ). Often, the relevant parameters from separate populations for metaanalysis may be derived from the literature or by collaboration. As more GWASs are performed and data become publicly available, metaanalyses without the need for additional experimentation becomes increasingly feasible (116, 117 ) .
Interpretation
Once initial discovery is complete and replication studies have validated the candidate associations, it is com-mon to ask whether the identified SNPs have a causal role in the association or whether they are simply in LD with a causal variant. If a candidate SNP appears to be functional (for example because it encodes an amino acid substitution or disrupts sequences with known or inferred biological function), a strong hypothesis may already exist for pursuing confirmatory experimental functional studies. Otherwise, it may be necessary to look for stronger associations at the candidate locus by genotyping additional variants chosen strategically from dbSNP or the HapMap, 2 publicly available repositories of SNP information. For some additional SNPs, genotypes may be estimated by purely computational methods through LD relationships in the HapMap (38, 53, 81, 118 ) . A more thorough job of finding the best candidates for biological function will often involve resequencing a candidate region to find SNPs that either were not included or were overlooked in the original analysis, often owing to low minor allele frequency (119 ) . This approach to follow-up has increasing appeal as high-throughput sequencing techniques continue to be more affordable.
The causal variant need not be a single SNP at all, however, but instead may be a combination of SNPs defining a haplotype or even copy number variants involving long-range perturbations in sequence. Whereas analytic methods exist for examining both of these possibilities, deciphering the precise causal relationships between complex patterns of variation and clinical analyte concentration will rarely be simple. Often, an unambiguous basis for causality may be deduced only by combining the genetic findings with experimental analysis in vitro or in vivo.
Detailed nature of the associated variation aside, one of the great hopes of GWAS technology is the identification of new functional relationships for both known genes and relatively unexplored parts of the genome. To be sure, the first series of published GWASs of plasma-based intermediate phenotypes have fulfilled this promise, and are furthering an understanding the networks of interconnected proteins that contribute to the concentration level of a clinical analyte (60, 69, 70, (92) (93) (94) 120 ) . For example, 1 recent GWAS of plasma CRP concentration (69 ), a marker of inflammation as well as vascular risk and diabetes, identified proteins previously recognized for roles in metabolic processes, including GCKR, LEPR (leptin receptor), HNF1A (HNF1 homeobox A), APOE (apolipoprotein E), CRP (C-reactive protein, pentraxin-related), and IL6R (interleukin-6 receptor) (Fig. 3A) . Thus, through the connection to plasma CRP concentrations, these data provide crucial genetic evidence for a biological pathway unifying inflammation and metabolic processes, and suggesting further links between diabetes and vascular disease. Alternatively, rather than suggesting new connections between known genes, some associations may suggest new functions for loci with the hallmarks of protein-encoding properties, but no known biological activity, and thus begin to place these genelike regions in a biological context. Finally, associations at loci lacking conventional genic structure begin to ascribe function to unannotated regions of the genome, as was suggested again by the genomewide association between a gene-free region of 12q23.2 and plasma CRP concentrations. Certainly, biological function for this region may be suspected from its high level of sequence conservation among vertebrates (Fig. 3B) .
Deeper understanding of biological function and disease processes may also be revealed by exploring whether the associations of candidate SNPs with plasma analytes can be extended to associations with a suitable clinical outcome (32, 94 ) . As with the initial GWAS, cohort design is crucial for the success of these studies, and must be carefully scrutinized to avoid confounding. Although effects on disease risk are expected to be modest, for example with relative risk estimates Ͻ2, the threshold for significance in these studies will be less stringent than in the initial GWAS, since only a few variants will likely be pursued, presenting only minimal burden of multiple hypothesis testing. Of course, discovering genes related to disease via analysis of clinical analytes raises the possibility of identifying new drug targets and therapeutic strategies.
Because the effects on disease of individual candidate variants arising from genetic studies of plasma analytes are expected to be small, some investigators have begun testing multiple candidates simultaneously, i.e., in aggregate. In one approach, test of association is performed by including a set of candidate SNPs as separate terms in a single (logistic) regression model and evaluating the total contribution of the genetic terms to risk. In another approach, one assumes that the effects of each SNP on disease status will be roughly equivalent, allowing the construction of a genetic risk score (GRS) as the count of risk alleles carried by an individual (121) (122) (123) . Including the GRS as the independent variable in hypothesis testing may yield only an average estimate of risk, but it may also reinforce a pathophysiologic link between a set of genes and a clinical analyte and disease that could not be established with any single candidate variant alone. In a recent example, 9 SNPs, selected for their effects on plasma lipid fractions, were used to construct a GRS associated with cardiovascular risk (95 ) .
Using genetics to establish true causality between a clinical analyte and disease is problematic, however. The idea, termed Mendelian randomization, is based on the assumption of a random assortment of alleles during mating, much the way drug treatment is randomly allocated in a clinical trial (124 ) . If the concen- 
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Reviews tration of a clinical analyte is associated with a SNP, it is argued, then a potential causal role of the analyte in disease can be tested by identifying an association between the SNP and disease directly. Although intuitively appealing and potentially informative, the idea is quite controversial for several reasons (125, 126 ) . First, there is considerable uncertainty in the relationship between the effects on clinical analyte concentrations in cross-sectional designs typical of GWASs and their effects on a longitudinal basis over a lifetime. Cross-sectional associations simply may not reflect time-varying levels, for example postprandial levels or levels in childhood and adulthood. Further, the impact of a clinical analyte on disease may itself have a longitudinal component that is not captured in cross-sectional analysis. For example, increased analyte concentrations may confer lower risk at some ages but higher risk at others, especially if the effects are modified by a second exposure from the environment or other genes. Second, the statistical power to detect associations of common variants on disease is often limited even when the effect of the same variants on a clinical analyte is strong enough for good power. For example, Fig. 2A shows adequate power in a GWAS with a few thousand individuals for effects explaining only 1%-2% in the variance in a clinical analyte, a very small amount of variation for detecting association with disease in a comparably sized sample. As a result of these limitations, many studies invoking Mendelian randomization are simply underpowered and unlikely to be informative about causal relationships.
Most importantly, given the interconnected nature of biochemical pathways, it is extremely unlikely for a genetic variant to affect levels of a clinical analyte without also simultaneously affecting other analytes and molecular processes, some of which may also influence disease. For example, a recently described variant in GCKR increases plasma concentrations of triglycerides, apoB, and plasma CRP, all risk factors for cardiovascular disease and diabetes (32, 69, 70 ) . This same variant, however, increases plasma concentrations of ApoA1 and decreases fasting glucose, trends that are protective of cardiovascular disease and diabetes (70, 127 ) . In this case, the relationship between any of these analytes alone and cardiovascular disease would be hard to discern based on the genetic data alone, even if adequate statistical power were available. Similarly, in the case of the GRS-constructed SNPs with effects on lipid fractions (see above), the association with risk persisted after adjustment of the lipid fractions themselves, suggesting additional effects of the genetic variation not captured by the cross-sectional measure of lipid concentration (95 ) . Given the caveats, one must conclude that a positive result in a Mendelian randomization analysis may suggest a causal link between an analyte and disease, but the absence of an effect is very difficult to interpret.
Conclusion
Recent technologies allow comprehensive survey of common variation in the human genome and its testing for association with plasma concentrations of clinical analytes. The first published reports using these technologies are discovering new functions for the genome and new hypotheses for understanding human biology and disease. If the human genome sequence has enabled technologies for GWAS, then the correlation of common genetic variation on a genomewide basis with clinical analytes, or any other outcome of interest, begins to reveal how the parts of the genome work together in human physiology. 
